{"entity":{"id":"rachel-kerr","kind":"person","name":"Rachel Kerr","aka":[],"tldr":"The Oxford oncologist who led QUASAR 2 and co-led SCOT, the trial that cut adjuvant chemotherapy for bowel cancer from six months to three without losing benefit.","summary":"Rachel Kerr is a medical oncologist and Associate Professor of Gastrointestinal Oncology in the University of Oxford's Department of Oncology, works at Oxford University Hospitals NHS Trust within the colorectal cancer multidisciplinary team, and is clinical director of phase 3 trials at the Oncology Clinical Trials Office. She was first author of QUASAR 2, which showed that adding bevacizumab to adjuvant capecitabine did not improve disease-free survival, and second author of SCOT, which found three months of adjuvant oxaliplatin-fluoropyrimidine chemotherapy non-inferior to six months with far less lasting peripheral neuropathy.","asOf":"2026-09-24","links":[{"label":"University of Oxford staff page","url":"https://www.oncology.ox.ac.uk/team/rachel-kerr"}],"tags":["colorectal","trialist","uk"],"related":["tim-maughan"],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine","oxaliplatin","capox","bevacizumab"],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":["quasar","scot"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Professor of Gastrointestinal Oncology, University of Oxford; Clinical Director of Phase 3 Trials, Oncology Clinical Trials Office","institutionId":"oxford-cancer","specialisms":["Adjuvant chemotherapy","Colorectal cancer trials","Trial methodology"],"profiles":[{"label":"University of Oxford staff page","url":"https://www.oncology.ox.ac.uk/team/rachel-kerr"}],"papers":[{"title":"Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30172-3"},{"title":"3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30093-7"}]},"route":"/people/rachel-kerr/","neighbours":{"person":[{"id":"tim-maughan","kind":"person","name":"Tim Maughan","route":"/people/tim-maughan/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"institution":[{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/"}],"trial":[{"id":"quasar","kind":"trial","name":"QUASAR","route":"/trials/quasar/"},{"id":"scot","kind":"trial","name":"SCOT","route":"/trials/scot/"}]}}